Q3 2025 13F Holders as of 30 Sep 2025
-
Type / Class
-
Equity / Common Stock, par value $0.001 per share
-
Shares outstanding
-
19,770,250
-
Number of holders
-
34
-
Total 13F shares, excl. options
-
2,357,676
-
Shares change
-
+1,739,775
-
Total reported value, excl. options
-
$6,053,256
-
Value change
-
+$4,553,396
-
Number of buys
-
22
-
Number of sells
-
-10
-
Price
-
$2.56
Significant Holders of BioXcel Therapeutics, Inc. - Common Stock, par value $0.001 per share (BTAI) as of Q3 2025
42 filings reported holding BTAI - BioXcel Therapeutics, Inc. - Common Stock, par value $0.001 per share as of Q3 2025.
BioXcel Therapeutics, Inc. - Common Stock, par value $0.001 per share (BTAI) has 34 institutional shareholders that have filed 13F forms with the Securities Exchange Commission (SEC).
These institutions hold a total of 2,357,676 shares
of 19,770,250 outstanding shares and own 11.93% of the company stock.
Largest 10 shareholders include MILLENNIUM MANAGEMENT LLC (1,028,053 shares), OAKTREE CAPITAL MANAGEMENT LP (241,188 shares), FMR LLC (198,600 shares), VANGUARD GROUP INC (192,125 shares), GEODE CAPITAL MANAGEMENT, LLC (125,240 shares), XTX Topco Ltd (113,364 shares), BlackRock, Inc. (84,282 shares), STATE STREET CORP (52,718 shares), UBS Group AG (43,542 shares), and Oaktree Fund Advisors, LLC (42,913 shares).
This table shows the top 34 institutional shareholders of the company equity. This data is sourced directly from the SEC via 13F filings.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price $ |
Shares |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.